O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

• G. Dore,
• J. Grebely,
• F. Altice,
• A.H. Litwin,
• O. Dalgard,
• E.J. Gane,
• O. Shibolet,
• A. Luetkemeyer,
• R. Nahass,
• C.Y. Peng,
• B. Conway,
• D.M. Iser,
• H.C. Huang,
• I.N. Gendrano,
• M. Kelly,
• P. Hwang,
• M. Robertson,
• J. Wahl,
• E. Barr,
• H.L. Platt

Affiliations

G. Dore

UNSW, Sydney, NSW, Australia

J. Grebely

UNSW, Sydney, NSW, Australia

F. Altice

Yale University, New Haven, CT, USA

A.H. Litwin

Albert Einstein/Montefiore Medical Center, Bronx, NY, USA

O. Dalgard

Akershus University, Oslo, Norway

E.J. Gane

Auckland City Hospital, Auckland, New Zealand

O. Shibolet

Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center and Tel-Aviv University, Tel-Aviv, Israel

A. Luetkemeyer

University of California, San Francisco, CA, USA

R. Nahass

ID Care, Hillsboro, NJ, USA

C.Y. Peng

China Medical University Hospital, Taichung, Taiwan

B. Conway

Vancouver Infectious Diseases Centre, Victoria, BC, Canada

D.M. Iser

St. Vincent‘s Hospital, Melbourne, VIC, Australia

H.C. Huang

Merck & Co., Inc., Kenilworth, NJ, USA.

I.N. Gendrano

Merck & Co., Inc., Kenilworth, NJ, USA.

M. Kelly

Merck & Co., Inc., Kenilworth, NJ, USA.

P. Hwang

Merck & Co., Inc., Kenilworth, NJ, USA.

M. Robertson

Merck & Co., Inc., Kenilworth, NJ, USA.

J. Wahl

Merck & Co., Inc., Kenilworth, NJ, USA.

E. Barr

Merck & Co., Inc., Kenilworth, NJ, USA.

H.L. Platt

Merck & Co., Inc., Kenilworth, NJ, USA.